These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17329266)

  • 21. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
    Lignell A; Löwdin E; Cars O; Sjölin J
    J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes.
    Ballesta S; García I; Perea EJ; Pascual A
    J Antimicrob Chemother; 2005 May; 55(5):785-7. PubMed ID: 15824095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive aspergillosis with polyarthritis.
    Mekan SF; Saeed O; Khan JA
    Mycoses; 2004 Dec; 47(11-12):518-20. PubMed ID: 15601460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
    Robatel C; Rusca M; Padoin C; Marchetti O; Liaudet L; Buclin T
    J Antimicrob Chemother; 2004 Jul; 54(1):269-70. PubMed ID: 15175271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
    Chryssanthou E; Loebig A; Sjölin J
    J Antimicrob Chemother; 2008 Jun; 61(6):1309-11. PubMed ID: 18367461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Brown J; Freeman BB
    Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
    [No Abstract]   [Full Text] [Related]  

  • 28. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans.
    Senthilkumari S; Lalitha P; Prajna NV; Haripriya A; Nirmal J; Gupta P; Velpandian T
    Curr Eye Res; 2010 Nov; 35(11):953-60. PubMed ID: 20958183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses.
    Colitz CM; Latimer FG; Cheng H; Chan KK; Reed SM; Pennick GJ
    Am J Vet Res; 2007 Oct; 68(10):1115-21. PubMed ID: 17916020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
    Araujo R; Coutinho I; Espinel-Ingroff A
    J Antimicrob Chemother; 2008 Dec; 62(6):1277-80. PubMed ID: 18824456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole.
    Sili U; Yilmaz M; Ferhanoglu B; Mert A
    Clin Infect Dis; 2007 Oct; 45(7):897-8. PubMed ID: 17806057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspergillus osteomyelitis: review of 12 cases identified by the Prospective Antifungal Therapy Alliance registry.
    Horn D; Sae-Tia S; Neofytos D
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):384-7. PubMed ID: 19249181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances against aspergillosis.
    Steinbach WJ; Stevens DA; Denning DW; Moss RB
    Clin Infect Dis; 2003 Oct; 37 Suppl 3():S155-6. PubMed ID: 12975750
    [No Abstract]   [Full Text] [Related]  

  • 34. EUCAST Technical Note on voriconazole.
    Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing
    Clin Microbiol Infect; 2008 Oct; 14(10):985-7. PubMed ID: 18828859
    [No Abstract]   [Full Text] [Related]  

  • 35. Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.
    Weiler S; Zoller H; Graziadei I; Vogel W; Bellmann-Weiler R; Joannidis M; Bellmann R
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3459-60. PubMed ID: 17606679
    [No Abstract]   [Full Text] [Related]  

  • 36. Does one voriconazole breakpoint suit all Candida species?
    Arendrup MC; Denning DW; Pfaller MA; Diekema DJ; Rex JH
    J Clin Microbiol; 2007 Jun; 45(6):2093; author reply 2094. PubMed ID: 17548458
    [No Abstract]   [Full Text] [Related]  

  • 37. Random plasma concentrations of voriconazole decline over time.
    Mulanovich V; Lewis RE; Raad II; Kontoyiannis DP
    J Infect; 2007 Nov; 55(5):e129-30. PubMed ID: 17804077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microdialysis as a tool to determine free kidney levels of voriconazole in rodents: a model to study the technique feasibility for a moderately lipophilic drug.
    Araujo BV; Silva CF; Haas SE; Dalla Costa T
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):876-81. PubMed ID: 18395391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicokinetics of voriconazole during massive intentional poisoning.
    Rozé H; Lafargue M; Joannes-Boyau O; Batoz H; Dromer C; Breilh D; Janvier G
    J Antimicrob Chemother; 2009 Sep; 64(3):662-3. PubMed ID: 19535384
    [No Abstract]   [Full Text] [Related]  

  • 40. Aspergillus fumigatus-related spondylodiscitis in a heart transplant patient successfully treated with voriconazole.
    Wéclawiak H; Garrouste C; Kamar N; Linas MD; Tall P; Dambrin C; Durand D; Rostaing L
    Transplant Proc; 2007 Oct; 39(8):2627-8. PubMed ID: 17954195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.